{
    "type": "ETP",
    "ucits": false,
    "replication_method": "synthetic",
    "leverage": true,
    "derivatives": true,
    "swaps": true,
    "inverse": true,
    "complex_factors": [
        "Leverage",
        "Inverse Exposure",
        "Synthetic Replication via Swaps",
        "Daily Reset and Compounding Effects",
        "Counterparty Risk",
        "Collateralised Debt Security Structure"
    ],
    "classification": "complex",
    "supporting_data": "The WisdomTree FTSE 100 2x Daily Short is a UCITS eligible Exchange Traded Product (ETP) that provides leveraged short exposure (-2x) to the FTSE 100 index. It achieves this exposure through fully collateralised swap agreements, explicitly described as a 'fully collateralised swap performance' structure. The product is a certificated, registered, collateralised debt security, not a traditional ETF, and is not UCITS compliant despite the eligibility statement. The replication method is synthetic, relying on swap agreements with counterparties, with collateral held at The Bank of New York Mellon to mitigate counterparty risk. The product uses daily leverage with a leverage factor of -2x, resetting daily, which introduces compounding effects and deviation from the underlying index performance over periods longer than one day. The product is classified as highest risk (7/7) and is intended only for informed investors with specific knowledge of leveraged and inverse products. The KIID and PRIIPs KID both warn that the product is 'not simple and may be difficult to understand,' highlighting the complexity. The product involves counterparty risk, liquidity risk, and credit risk associated with the swap counterparties. The costs include management fees and transaction costs but no performance fees. The product is designed for short-term holding (recommended 1 day) due to the daily reset and compounding effects. The presence of leverage, inverse exposure, synthetic replication via swaps, and the collateralised debt security structure all contribute to the classification as a complex financial instrument under MiFID II. There is no indication that derivatives are used solely for risk management; rather, they are fundamental to the product's strategy. The product's complexity is further underscored by the need for investors to understand daily rebalancing, compounding, and the risks of leveraged inverse exposure. Therefore, the classification is 'complex' in line with MiFID II criteria."
}